Segal Ori, Ferencz Joseph R, Cohen Perri, Nemet Arie Y, Nesher Ronit
Department of Ophthalmology, Meir Medical Center, Kfar Saba, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Isr Med Assoc J. 2013 Jul;15(7):352-5.
The number of patients treated with intravitreal injections has increased significantly over the past few years, mainly following the introduction of anti-vascular endothelial growth factor antibody intraocular drugs. Bevacizumab is mostly used in this group of medications.
To describe persistent elevation of intraocular pressure (IOP) following intravitreal injection of bevacizumab.
We reviewed consecutive cases of persistent IOP elevation after intravitreal bevacizumab injection for exudative age-related macular degeneration (AMD). A total of 424 patients (528 eyes) met the inclusion criteria and received 1796 intravitreal injections of bevacizumab. Persistent IOP elevation was found in 19 eyes (3.6%, 19/528) of 18 patients (4.2%, 18/424) with IOP elevated 30-70 mmHg 3-30 days after injection.
Mean IOP was 42.6 mmHg (range 30-70); IOP elevations occurred after an average of 7.8 injections of bevacizumab (range 3-13). Injected eyes (19/528) had a significantly higher incidence of elevated IOP than uninjected eyes (fellow eyes), 1/328, P < 0.001.
Like other anti-vascular endothelial growth factor (VEGF) substances reported in a few recent studies, intravitreal injection of bevacizumab for neovascular AMD may be associated with persistent IOP elevation. Providers should be aware that significant IOP elevation might occur after repeated treatments.
在过去几年中，接受玻璃体内注射治疗的患者数量显著增加，这主要是在抗血管内皮生长因子抗体眼内药物引入之后。贝伐单抗在这类药物中使用最为广泛。
描述玻璃体内注射贝伐单抗后眼压持续升高的情况。
我们回顾了玻璃体内注射贝伐单抗治疗渗出性年龄相关性黄斑变性（AMD）后眼压持续升高的连续病例。共有424例患者（528只眼）符合纳入标准，并接受了1796次玻璃体内贝伐单抗注射。在18例患者（4.2%，18/424）的19只眼（3.6%，19/528）中发现眼压持续升高，注射后3至30天眼压升高30 - 70 mmHg。
平均眼压为42.6 mmHg（范围30 - 70）；眼压升高平均发生在7.8次贝伐单抗注射后（范围3 - 13）。注射眼（19/528）眼压升高的发生率显著高于未注射眼（对侧眼），为1/328，P < 0.001。
与最近一些研究中报道的其他抗血管内皮生长因子（VEGF）物质一样，玻璃体内注射贝伐单抗治疗新生血管性AMD可能与眼压持续升高有关。医疗人员应意识到，重复治疗后可能会出现显著的眼压升高。
